Wipfli Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wipfli Financial Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$82K	Buy	+196	New	+$97.7K	0.01%	822

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wipfli Financial Advisors's BIO Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2022: 196 shares worth $82K. The stake represents 0.01% of the portfolio and ranks #822 among its holdings.

485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

Wipfli Financial Advisors held 196 shares of Bio-Rad Laboratories Class A worth $82K as of Q3 2022.
Bio-Rad Laboratories Class A was a new Wipfli Financial Advisors position in Q3 2022.
Bio-Rad Laboratories Class A made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #822 holding.
485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.